Getinge AB (publ)

LSE:0GZV Stock Report

Market Cap: SEK 51.4b

Getinge Valuation

Is 0GZV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0GZV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 385.51
Fair Value
50.8% undervalued intrinsic discount
9
Number of Analysts

Below Fair Value: 0GZV (SEK189.61) is trading below our estimate of fair value (SEK385.51)

Significantly Below Fair Value: 0GZV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0GZV?

Key metric: As 0GZV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0GZV. This is calculated by dividing 0GZV's market cap by their current earnings.
What is 0GZV's PE Ratio?
PE Ratio30.4x
EarningsSEK 1.69b
Market CapSEK 51.37b

Price to Earnings Ratio vs Peers

How does 0GZV's PE Ratio compare to its peers?

The above table shows the PE ratio for 0GZV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.4x
SN. Smith & Nephew
34.5x22.6%UK£8.6b
NIOX NIOX Group
21.1x15.8%UK£232.4m
EKF EKF Diagnostics Holdings
25.2xn/aUK£120.2m
CTEC ConvaTec Group
36.6x20.3%UK£4.6b
0GZV Getinge
30.4x21.5%SEK 51.4b

Price-To-Earnings vs Peers: 0GZV is expensive based on its Price-To-Earnings Ratio (30.4x) compared to the peer average (29.4x).

Price to Earnings Ratio vs Industry

How does 0GZV's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0GZV 30.4xIndustry Avg. 30.8xNo. of Companies9PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0GZV is good value based on its Price-To-Earnings Ratio (30.4x) compared to the European Medical Equipment industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0GZV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0GZV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.4x
Fair PE Ratio39.3x

Price-To-Earnings vs Fair Ratio: 0GZV is good value based on its Price-To-Earnings Ratio (30.4x) compared to the estimated Fair Price-To-Earnings Ratio (39.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0GZV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 189.61
SEK 221.11
+16.6%
17.9%SEK 300.00SEK 160.00n/a9
Jan ’26SEK 183.02
SEK 220.78
+20.6%
17.7%SEK 300.00SEK 160.00n/a9
Dec ’25SEK 169.79
SEK 221.67
+30.6%
16.8%SEK 300.00SEK 180.00n/a9
Nov ’25SEK 187.09
SEK 225.44
+20.5%
16.0%SEK 300.00SEK 180.00n/a9
Oct ’25SEK 218.83
SEK 233.00
+6.5%
14.0%SEK 300.00SEK 190.00n/a8
Sep ’25SEK 213.10
SEK 230.00
+7.9%
14.2%SEK 300.00SEK 190.00n/a8
Aug ’25SEK 206.79
SEK 230.00
+11.2%
14.2%SEK 300.00SEK 190.00n/a8
Jul ’25SEK 180.83
SEK 225.44
+24.7%
15.8%SEK 290.00SEK 165.00n/a9
Jun ’25SEK 186.99
SEK 229.22
+22.6%
13.2%SEK 300.00SEK 186.00n/a9
May ’25SEK 235.00
SEK 235.50
+0.2%
12.2%SEK 300.00SEK 186.00n/a10
Apr ’25SEK 215.40
SEK 226.10
+5.0%
14.9%SEK 300.00SEK 164.00n/a10
Mar ’25SEK 205.25
SEK 227.10
+10.6%
15.2%SEK 300.00SEK 164.00n/a10
Feb ’25SEK 200.06
SEK 236.60
+18.3%
11.3%SEK 300.00SEK 210.00n/a10
Jan ’25SEK 224.30
SEK 228.56
+1.9%
12.8%SEK 300.00SEK 190.00SEK 183.029
Dec ’24SEK 225.22
SEK 220.33
-2.2%
17.4%SEK 300.00SEK 150.00SEK 169.799
Nov ’24SEK 201.19
SEK 210.89
+4.8%
14.7%SEK 250.00SEK 150.00SEK 187.099
Oct ’24SEK 192.70
SEK 203.11
+5.4%
16.1%SEK 250.00SEK 134.00SEK 218.839
Sep ’24SEK 190.20
SEK 203.11
+6.8%
16.1%SEK 250.00SEK 134.00SEK 213.109
Aug ’24SEK 198.88
SEK 203.11
+2.1%
16.1%SEK 250.00SEK 134.00SEK 206.799
Jul ’24SEK 188.95
SEK 230.40
+21.9%
19.9%SEK 300.00SEK 139.00SEK 180.8310
Jun ’24SEK 251.30
SEK 265.30
+5.6%
11.8%SEK 300.00SEK 193.00SEK 186.9910
May ’24SEK 255.45
SEK 260.33
+1.9%
11.6%SEK 295.00SEK 193.00SEK 235.009
Apr ’24SEK 252.66
SEK 252.89
+0.09%
8.6%SEK 285.00SEK 208.00SEK 215.409
Mar ’24SEK 218.30
SEK 253.44
+16.1%
8.1%SEK 285.00SEK 208.00SEK 205.259
Feb ’24SEK 241.41
SEK 252.89
+4.8%
7.9%SEK 285.00SEK 208.00SEK 200.069
Jan ’24SEK 218.40
SEK 264.33
+21.0%
5.5%SEK 285.00SEK 240.00SEK 224.309
Analyst Price Target
Consensus Narrative from 9 Analysts
SEK 222.29
Fair Value
14.7% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 13:34
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Getinge AB (publ) is covered by 33 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sten GustafssonABG Sundal Collier
Kamla SinghAlphaValue
Scott BardoBerenberg